The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment
- 2 January 2023
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 70, 104497
Abstract
No abstract availableKeywords
Funding Information
- Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston
- Genentech (ML41627)
- Health Science Center, University of North Texas
- National Center for Advancing Translational Sciences
- Center for Clinical and Translational Science, University of Illinois at Chicago (UL1TR003167)
This publication has 14 references indexed in Scilit:
- Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging ImmunotherapiesTrends in Molecular Medicine, 2020
- T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early interventionBrain, 2018
- Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteinsJournal of Neuroimmunology, 2017
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisNew England Journal of Medicine, 2017
- The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteinsJournal of Neuroimmunology, 2016
- Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein LMolecular Immunology, 2016
- Role of Th17 cells in the pathogenesis of CNS inflammatory demyelinationJournal of the Neurological Sciences, 2013
- The antibody response to Epstein–Barr virions is altered in multiple sclerosisJournal of Neuroimmunology, 2012
- Duration of Humoral Immunity to Common Viral and Vaccine AntigensNew England Journal of Medicine, 2007
- Multiple Sclerosis Is an Inflammatory T-Cell–Mediated Autoimmune DiseaseArchives of Neurology, 2004